🟢 Moderna is trading 11.26% up in after-hours trading after positive Phase 3 melanoma vaccine results

Moderna is trading at $194.02 (+11.26%) after the company and Merck reported positive Phase 3 results for their personalized mRNA melanoma vaccine.

• INTerpath-001 met recurrence-free and distant-metastasis-free survival endpoints.
• The treatment combines Moderna’s intismeran with Merck’s Keytruda, marking the first positive Phase 3 outcome for this personalized mRNA cancer approach.
• The regular session had already gained 176.97% on August 19, 2026.